이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

신세포암(MK-6482-011) 치료를 위한 렌바티닙과 카보잔티닙의 병용요법에 대한 벨주티판(MK-6482) 연구

2026년 11월 4일 업데이트: Merck Sharp & Dohme LLC

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.

The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

747

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Thessaloniki, 그리스, 570 01
        • European Interbalkan Medical Center-Oncology Department ( Site 3300)
    • Achaia
      • Pátrai, Achaia, 그리스, 26504
        • UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 3302)
    • Attica
      • Athens, Attica, 그리스, 115 28
        • Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 3304)
      • Athens, Attica, 그리스, 151 25
        • Athens Medical Center ( Site 3303)
      • Chaïdári, Attica, 그리스, 124 62
        • ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 3301)
      • Utrecht, 네덜란드, 3584 CX
        • Universitair Medisch Centrum Utrecht ( Site 1910)
    • Limburg
      • Sittard-Geleen, Limburg, 네덜란드, 6162 BG
        • Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1904)
    • North Brabant
      • Breda, North Brabant, 네덜란드, 4818 CK
        • Amphia Hospital Location Molengracht ( Site 1912)
    • North Holland
      • Amsterdam, North Holland, 네덜란드, 1066 CX
        • Antoni van Leeuwenhoek Ziekenhuis ( Site 1901)
    • Provincie Friesland
      • Leeuwarden, Provincie Friesland, 네덜란드, 8934 AD
        • Medisch Centrum Leeuwarden ( Site 1905)
    • South Holland
      • Rotterdam, South Holland, 네덜란드, 3015 GD
        • Erasmus MC ( Site 1913)
      • Schiedam, South Holland, 네덜란드, 3118 JH
        • Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1909)
      • The Hague, South Holland, 네덜란드, 2545 AA
        • Haga Ziekenhuis locatie Leyweg-Oncology ( Site 1917)
      • Seoul, 대한민국, 05505
        • Asan Medical Center ( Site 4200)
      • Seoul, 대한민국, 06351
        • Samsung Medical Center ( Site 4201)
    • Jeonranamdo
      • Hwasun, Jeonranamdo, 대한민국, 58128
        • Chonnam National University Hwasun Hospital-Oncology ( Site 4203)
      • Berlin, 독일, 10117
        • Charite Universitaetsmedizin Berlin ( Site 1321)
      • Berlin, 독일, 13125
        • HELIOS Klinikum Berlin-Buch ( Site 1311)
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, 독일, 79106
        • Klinik fuer Urologie ( Site 1303)
      • Heidelberg, Baden-Wurttemberg, 독일, 69120
        • NCT-Department of Medical Oncology ( Site 1320)
    • Bavaria
      • Nuremberg, Bavaria, 독일, 90419
        • Klinikum Nuernberg Nord ( Site 1300)
    • Hesse
      • Frankfurt am Main, Hesse, 독일, 60590
        • Universitaetsklinikum Frankfurt ( Site 1301)
    • North Rhine-Westphalia
      • Aachen, North Rhine-Westphalia, 독일, 52074
        • Universitaetsklinikum Aachen AOER ( Site 1317)
    • Saarland
      • Homburg/ Saar, Saarland, 독일, 66421
        • Universitaetsklinikum des Saarlandes ( Site 1305)
    • Saxony-Anhalt
      • Halle, Saxony-Anhalt, 독일, 06120
        • Krankenhaus Martha Maria Halle-Doelau ( Site 1314)
    • Thuringia
      • Erfurt, Thuringia, 독일, 99089
        • Helios Klinikum Erfurt GmbH ( Site 1315)
    • Ivanovo Oblast
      • Ivanovo, Ivanovo Oblast, 러시아 제국, 153040
        • Ivanovo Regional Oncology Dispensary ( Site 2616)
    • Moscow
      • Moscow, Moscow, 러시아 제국, 119285
        • FSBI United Hospital with Polyclinic ( Site 2613)
      • Moscow, Moscow, 러시아 제국, 125130
        • SHI of Moscow City Oncology Clinical Hospital - 62 ( Site 2614)
    • Moscow Oblast
      • Krasnogorsk, Moscow Oblast, 러시아 제국, 143442
        • MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 2618)
      • Moscow, Moscow Oblast, 러시아 제국, 121205
        • Hadassah Medical-Oncology department ( Site 2609)
    • Volgograd Oblast
      • Volzhsky, Volgograd Oblast, 러시아 제국, 404120
        • Volgograd Regional Uronephrological Center ( Site 2615)
    • Yaroslavl Oblast
      • Yaroslavl, Yaroslavl Oblast, 러시아 제국, 150054
        • Yaroslavl Regional Cancer Hospital-Oncology ( Site 2619)
    • Cluj
      • Cluj-Napoca, Cluj, 루마니아, 400015
        • Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2500)
      • Cluj-Napoca, Cluj, 루마니아, 400015
        • Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2501)
    • Dolj
      • Craiova, Dolj, 루마니아, 200542
        • Centrul de Oncologie "Sfântul Nectarie" ( Site 2502)
    • Arizona
      • Chandler, Arizona, 미국, 85224
        • Ironwood Cancer & Research Centers ( Site 0077)
    • California
      • Los Angeles, California, 미국, 90048
        • Cedars Sinai Medical Center ( Site 0027)
      • Los Angeles, California, 미국, 90404
        • UCLA Hematology/Oncology - Santa Monica ( Site 0048)
      • Orange, California, 미국, 92868
        • St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095)
      • Orange, California, 미국, 92868
        • University of California, Irvine ( Site 0029)
      • Santa Monica, California, 미국, 90404
        • Providence Saint John's Health Center ( Site 0083)
    • District of Columbia
      • Washington D.C., District of Columbia, 미국, 20007
        • Georgetown University Medical Center ( Site 0006)
    • Florida
      • Orlando, Florida, 미국, 32806
        • Orlando Health, Inc. ( Site 0035)
      • Orlando, Florida, 미국, 32804
        • AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0003)
    • Georgia
      • Athens, Georgia, 미국, 30607
        • University Cancer & Blood Center, LLC ( Site 0057)
      • Atlanta, Georgia, 미국, 30322
        • Emory University Hospital ( Site 0012)
    • Illinois
      • Chicago, Illinois, 미국, 60607
        • Rush University Medical Center ( Site 0040)
      • Peoria, Illinois, 미국, 61615
        • Illinois Cancer Care, PC ( Site 0008)
    • Indiana
      • Fort Wayne, Indiana, 미국, 46845
        • Parkview Cancer Institute ( Site 0088)
    • Kentucky
      • Louisville, Kentucky, 미국, 40207
        • Norton Cancer Institute - St. Matthews ( Site 0065)
    • Louisiana
      • New Orleans, Louisiana, 미국, 70112
        • Tulane University School of Medicine ( Site 0098)
    • Massachusetts
      • Burlington, Massachusetts, 미국, 01805
        • Lahey Hospital & Medical Center ( Site 0090)
    • Michigan
      • Grand Rapids, Michigan, 미국, 49503
        • Cancer & Hematology Centers of Western Michigan ( Site 0018)
    • Minnesota
      • Saint Louis Park, Minnesota, 미국, 55426
        • HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005)
    • Mississippi
      • Jackson, Mississippi, 미국, 39213
        • University of Mississippi Medical Ctr ( Site 0037)
    • Nebraska
      • Lincoln, Nebraska, 미국, 68516
        • Cancer Partners of Nebraska ( Site 0086)
    • New Jersey
      • New Brunswick, New Jersey, 미국, 08903
        • Rutgers Cancer Institute of New Jersey ( Site 0078)
    • New York
      • Lake Success, New York, 미국, 11042
        • R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0013)
      • New York, New York, 미국, 10065
        • Memorial Sloan Kettering Cancer Center ( Site 0055)
    • North Carolina
      • Charlotte, North Carolina, 미국, 28204
        • Levine Cancer Institute ( Site 0004)
      • Durham, North Carolina, 미국, 27710
        • Duke Cancer Institute ( Site 0096)
    • Pennsylvania
      • Allentown, Pennsylvania, 미국, 18103
        • Lehigh Valley Hospital- Cedar Crest-Oncology Clinical Trials ( Site 0056)
    • Texas
      • Dallas, Texas, 미국, 75235
        • University of Texas, Southwestern Medical Center ( Site 0015)
    • Utah
      • Salt Lake City, Utah, 미국, 84112
        • Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 7001)
    • Vermont
      • Burlington, Vermont, 미국, 05401
        • University of Vermont Medical Center ( Site 0001)
    • Virginia
      • Roanoke, Virginia, 미국, 24014
        • Blue Ridge Cancer Care - Roanoke ( Site 0043)
    • Washington
      • Seattle, Washington, 미국, 98109
        • Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 0093)
      • Wenatchee, Washington, 미국, 98801
        • Central Washington Health Services Association d/b/a Confluence Health ( Site 0061)
      • Liège, 벨기에, 4000
        • CHU de Liege ( Site 1102)
    • Bruxelles-Capitale, Region de
      • Anderlecht, Bruxelles-Capitale, Region de, 벨기에, 1070
        • Institut Jules Bordet ( Site 1103)
      • Brussels, Bruxelles-Capitale, Region de, 벨기에, 1200
        • Cliniques Universitaires Saint Luc - Bruxelles ( Site 1105)
    • Hainaut
      • Gilly, Hainaut, 벨기에, 6060
        • Grand Hopital de Charleroi ( Site 1104)
    • Oost-Vlaanderen
      • Ghent, Oost-Vlaanderen, 벨기에, 9000
        • UZ Gent ( Site 1100)
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, 벨기에, 3000
        • UZ Leuven ( Site 1101)
      • São Paulo, 브라질, 01321-001
        • BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0311)
      • São Paulo, 브라질, 01321-001
        • Hospital Paulistano - Amil Clinical Research ( Site 0308)
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, 브라질, 59151600
        • Liga Norte Riograndense Contra o Cancer ( Site 0313)
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, 브라질, 90110-270
        • Centro Gaucho Integrado de Oncologia ( Site 0304)
    • Canton Ticino
      • Bellinzona, Canton Ticino, 스위스, 6500
        • Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1604)
    • Canton of Geneva
      • Geneva, Canton of Geneva, 스위스, 1211
        • Hopitaux Universitaires de Geneve HUG ( Site 1602)
    • Canton of Zurich
      • Zurich, Canton of Zurich, 스위스, 8001
        • Universitaetsspital Zuerich ( Site 1601)
    • Kanton Graubünden
      • Chur, Kanton Graubünden, 스위스, 7000
        • Kantonsspital Graubuenden ( Site 1600)
      • Barcelona, 스페인, 08035
        • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1507)
      • Barcelona, 스페인, 08036
        • Hospital Clinic i Provincial ( Site 1500)
      • Barcelona, 스페인, 08041
        • Hospital Santa Creu i Sant Pau ( Site 1501)
      • Madrid, 스페인, 28009
        • Hospital General Universitario Gregorio Maranon ( Site 1505)
      • Madrid, 스페인, 28040
        • Hospital Clinico San Carlos... ( Site 1504)
      • Seville, 스페인, 41013
        • Hospital Virgen del Rocio ( Site 1503)
    • La Coruna
      • A Coruña, La Coruna, 스페인, 15006
        • Complejo Hospitalario Universitario A Coruna ( Site 1502)
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, 스페인, 28041
        • Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1508)
    • Buenos Aires
      • CABA, Buenos Aires, 아르헨티나, C1120AAT
        • Centro de Urología (CDU) ( Site 0803)
      • Ciudad Autónoma de Buenos Aires, Buenos Aires, 아르헨티나, C1280AEB
        • Hospital Británico de Buenos Aires-Oncology ( Site 0801)
      • Ciudad Autónoma de Buenos Aires, Buenos Aires, 아르헨티나, C1426ANZ
        • Instituto Alexander Fleming ( Site 0800)
    • Buenos Aires F.D.
      • Buenos Aires, Buenos Aires F.D., 아르헨티나, C1419AHN
        • Asociación de Beneficencia Hospital Sirio Libanés ( Site 0804)
    • Santa Fe Province
      • Rosario, Santa Fe Province, 아르헨티나, 2000
        • Sanatorio Británico-Clinical Oncology Department ( Site 0802)
      • Rosario, Santa Fe Province, 아르헨티나, S2000DSV
        • Sanatorio Parque ( Site 0806)
      • Dublin, 아일랜드, D24NR0A
        • Tallaght University Hospital ( Site 3200)
      • Dublin, 아일랜드, D07 R2WY
        • Mater Misericordiae University Hospital ( Site 3201)
      • Dublin, 아일랜드, D07 R2WY
        • Mater Private Hospital - Dublin ( Site 3202)
    • Aberdeen City
      • Aberdeen, Aberdeen City, 영국, AB25 2ZN
        • Aberdeen Royal Infirmary-Department of Oncology ( Site 3105)
    • Bath And North East Somerset
      • Bath, Bath And North East Somerset, 영국, BA1 3NG
        • Royal United Hospital Bath England ( Site 3108)
    • England
      • Nottingham, England, 영국, NG5 1PF
        • Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 3106)
    • Essex
      • Southend, Essex, 영국, SS0 0RY
        • Southend University Hospital ( Site 3112)
    • London, City of
      • London, London, City of, 영국, W6 8RF
        • Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 3107)
      • Northwood, London, City of, 영국, HA6 2RN
        • Mount Vernon Cancer Centre ( Site 3101)
    • Somerset
      • Taunton, Somerset, 영국, TA1 5DA
        • Musgrove Park Hospital ( Site 3103)
    • Wales
      • Swansea, Wales, 영국, SA2 8QA
        • Singleton Hospital ( Site 3111)
      • Vienna, 오스트리아, 1020
        • Krankenhaus der Barmherzigen Brüder Wien ( Site 1041)
      • Vienna, 오스트리아, 1090
        • Medizinische Universität Wien ( Site 1021)
    • State of Vienna
      • Vienna, State of Vienna, 오스트리아, 1160
        • Klinik Ottakring-1.Medizinische Abteilung - Zentrum für Onkologie und Hämatologie ( Site 1031)
    • Styria
      • Graz, Styria, 오스트리아, 8036
        • Medizinische Universitätsklinik Graz ( Site 1051)
    • Upper Austria
      • Linz, Upper Austria, 오스트리아, 4020
        • Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 1001)
      • Arezzo, 이탈리아, 52100
        • Medical Oncology Ospedale San Donato ( Site 1404)
      • Bari, 이탈리아, 70124
        • Azienda Ospedaliera Policlinico di Bari ( Site 1402)
      • Milan, 이탈리아, 20132
        • IRCCS Ospedale San Raffaele ( Site 1409)
      • Milan, 이탈리아, 20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1400)
      • Pavia, 이탈리아, 27100
        • Istituti Clinici Scientifici Maugeri Spa ( Site 1403)
      • Roma, 이탈리아, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1410)
      • Terni, 이탈리아, 05100
        • Azienda Ospedaliera S. Maria di Terni ( Site 1401)
      • Verona, 이탈리아, 37126
        • Ospedale Maggiore Borgo Trento ( Site 1408)
    • Forli-Cesena
      • Meldola, Forli-Cesena, 이탈리아, 47014
        • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 1407)
    • Milano
      • Rozzano, Milano, 이탈리아, 20089
        • Istituto Clinico Humanitas Research Hospital ( Site 1406)
    • Torino
      • Orbassano, Torino, 이탈리아, 10043
        • Ospedale San Luigi Gonzaga ( Site 1405)
      • Fukuoka, 일본, 812-8582
        • Kyushu University Hospital ( Site 5005)
      • Niigata, 일본, 951-8520
        • Niigata University Medical & Dental Hospital ( Site 5013)
      • Osaka, 일본, 541-8567
        • Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 5016)
      • Tokyo, 일본, 113-8603
        • Nippon Medical School Hospital ( Site 5006)
      • Tokyo, 일본, 123-8558
        • Tokyo Women's Medical University Adachi Medical Center ( Site 5015)
      • Tokyo, 일본, 160-8582
        • Keio University Hospital ( Site 5011)
    • Aichi-ken
      • Toyoake, Aichi-ken, 일본, 470-1192
        • Fujita Health University Hospital ( Site 5003)
    • Chiba
      • Kashiwa, Chiba, 일본, 2778577
        • National Cancer Center Hospital East ( Site 5000)
      • Sakura, Chiba, 일본, 285-8741
        • Toho University Sakura Medical Center ( Site 5014)
    • Hokkaido
      • Sapporo, Hokkaido, 일본, 060-8543
        • Sapporo Medical University Hospital ( Site 5008)
    • Hyōgo
      • Kobe, Hyōgo, 일본, 650-0047
        • Kobe City Medical Center General Hospital ( Site 5017)
    • Kanagawa
      • Yokohama, Kanagawa, 일본, 236-0004
        • Yokohama City University Hospital ( Site 5007)
    • Nara
      • Kashihara, Nara, 일본, 634-0813
        • Nara Medical University Hospital ( Site 5002)
    • Osaka
      • Sakai, Osaka, 일본, 590-0197
        • Kindai University Hospital ( Site 5010)
      • Suita, Osaka, 일본, 565-0871
        • The University of Osaka Hospital ( Site 5012)
    • Shizuoka
      • Hamamatsu, Shizuoka, 일본, 431-3192
        • Hamamatsu University Hospital ( Site 5004)
    • Tokyo
      • Bunkyo-ku, Tokyo, 일본, 113-8510
        • Institute of Science Tokyo Hospital ( Site 5009)
      • Minato-ku, Tokyo, 일본, 105-8470
        • Toranomon Hospital ( Site 5001)
      • Hradec Králové, 체코, 500 05
        • Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie ( Site 2201)
    • Brno-mesto
      • Brno, Brno-mesto, 체코, 656 53
        • Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 2203)
    • Praha 4
      • Prague, Praha 4, 체코, 140 59
        • Fakultni Thomayerova nemocnice-Onkologicka klinika 1. LF UK ( Site 2200)
    • Praha 5
      • Prague, Praha 5, 체코, 150 06
        • Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 2205)
    • South Bohemian Region
      • České Budějovice, South Bohemian Region, 체코, 37001
        • Nemocnice Ceske Budejovice-Onkologicke oddeleni ( Site 2204)
    • Araucania
      • Temuco, Araucania, 칠레, 4800827
        • James Lind Centro de Investigacion del Cancer ( Site 0402)
    • Region M. de Santiago
      • Santiago, Region M. de Santiago, 칠레, 8420383
        • Bradfordhill-Clinical Area ( Site 0400)
    • Alberta
      • Calgary, Alberta, 캐나다, T2N 5G2
        • Arthur J.E. Child Comprehensive Cancer Centre ( Site 0109)
      • Edmonton, Alberta, 캐나다, T6G 1Z2
        • Cross Cancer Institute ( Site 0111)
    • British Columbia
      • Vancouver, British Columbia, 캐나다, V5Z 4E6
        • BC Cancer Vancouver-Clinical Trials Unit ( Site 0110)
    • New Brunswick
      • Moncton, New Brunswick, 캐나다, E1C 6Z8
        • The Moncton Hospital ( Site 0101)
    • Ontario
      • Hamilton, Ontario, 캐나다, L8V 5C2
        • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0114)
      • Kingston, Ontario, 캐나다, K7L 2V7
        • Kingston Health Sciences Centre ( Site 0105)
      • Ottawa, Ontario, 캐나다, K1H 8L6
        • The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0116)
      • Toronto, Ontario, 캐나다, M4N 3M5
        • Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0113)
    • Quebec
      • Greenfield Park, Quebec, 캐나다, J4V 2H1
        • CISSS de la Monteregie-Centre ( Site 0103)
      • Québec, Quebec, 캐나다, G1J 1Z4
        • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0115)
      • Sherbrooke, Quebec, 캐나다, J1H 5N4
        • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0102)
    • Antioquia
      • Medellín, Antioquia, 콜롬비아, 050030
        • Fundacion Colombiana de Cancerología Clinica Vida ( Site 0505)
    • Cesar Department
      • Valledupar, Cesar Department, 콜롬비아, 200001
        • Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 0508)
    • Cundinamarca
      • Bogotá, Cundinamarca, 콜롬비아, 111511
        • Instituto Nacional de Cancerología-Clinical Oncology ( Site 0500)
    • Santander Department
      • Piedecuesta, Santander Department, 콜롬비아, 681017
        • Fundación Cardiovascular de Colombia ( Site 0501)
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, 폴란드, 60-569
        • Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 2401)
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 폴란드, 85-796
        • Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 2402)
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, 폴란드, 31-115
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - O-Klinika Onkologii Klinicznej ( Site 2403)
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, 폴란드, 02-781
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2400)
      • Paris, 프랑스, 75020
        • Hopital Tenon ( Site 1213)
    • Ain
      • Reims, Ain, 프랑스, 51726
        • Institut Jean Godinot ( Site 1216)
    • Alpes-Maritimes
      • Nice, Alpes-Maritimes, 프랑스, 06189
        • Centre Antoine Lacassagne ( Site 1217)
    • Bas-Rhin
      • Strasbourg, Bas-Rhin, 프랑스, 67200
        • Hopitaux Universitaires de Strasbourg- Hopital de Hautepierre ( Site 1218)
    • Gironde
      • Bordeaux, Gironde, 프랑스, 33000
        • CHU de Bordeaux- Hopital Saint Andre ( Site 1209)
    • Haute-Garonne
      • Toulouse, Haute-Garonne, 프랑스, 31059
        • Institut Claudius Regaud ( Site 1215)
    • Haute-Vienne
      • Limoges, Haute-Vienne, 프랑스, 87039
        • Clinique Francois Chenieux ( Site 1210)
    • Loire-Atlantique
      • Saint-Herblain, Loire-Atlantique, 프랑스, 44805
        • Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 1201)
    • Maine-et-Loire
      • Angers, Maine-et-Loire, 프랑스, 49055
        • Institut de Cancerologie de l Ouest Site Paul Papin ( Site 1200)
    • Pirkanmaa
      • Tampere, Pirkanmaa, 핀란드, 33520
        • Tampereen yliopistollinen sairaala ( Site 1801)
    • Southwest Finland
      • Turku, Southwest Finland, 핀란드, 20520
        • TYKS ( Site 1802)
    • Uusimaa
      • Helsinki, Uusimaa, 핀란드, 00290
        • HYKS ( Site 1800)
    • New South Wales
      • St Leonards, New South Wales, 호주, 2065
        • GenesisCare North Shore ( Site 4011)
    • South Australia
      • Elizabeth Vale, South Australia, 호주, 5112
        • Lyell McEwin Hospital ( Site 4004)
    • Victoria
      • Frankston, Victoria, 호주, 3199
        • Peninsula Health Frankston Hospital ( Site 4001)
      • Melbourne, Victoria, 호주, 3000
        • Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 4010)

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC)
  • Disease progression on or after an anti-programmed cell death-1/ligand 1 (PD-1/L1) therapy as either first or second-line treatment for locally advanced/metastatic RCC or as adjuvant treatment or neoadjuvant/adjuvant with progression on or within 6 months of last dose
  • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria as assessed by local study investigator
  • Karnofsky performance status (KPS) score of at least 70% assessed within 10 days before randomization
  • Received no more than 2 prior systemic regimens including: one anti-PD-1/L1 containing adjuvant or neoadjuvant/adjuvant regimens with progression on or within 6 months from the last dose of that regimen OR one or 2 regimens for locoregional/advanced disease
  • Received only 1 prior antiPD-1/L1 therapy for adjuvant, neoadjuvant/adjuvant or locally advanced/metastatic RCC
  • A male participant is eligible to participate if he is abstinent from heterosexual intercourse or agrees to use contraception during the intervention period and for at least 7 days after the last dose of belzutifan or lenvatinib in the belzutifan+lenvatinib arm, whichever occurs last, and 23 days after the last dose of cabozantinib
  • A female participant is eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 30 days after the last dose of study intervention in the belzutifan+ lenvatinib arm, or 120 days after the last dose of study intervention in the cabozantinib arm
  • Adequately controlled blood pressure
  • Adequate organ function

Exclusion Criteria:

  • A pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
  • Known additional malignancy that is progressing or has required active treatment within the past 3 years except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy
  • Known central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Clinically significant cardiac disease within 6 months of first dose of study intervention
  • Prolongation of corrected QT interval (QTc) interval to >480 ms.
  • Symptomatic pleural effusion (e.g.,cough, dyspnea, pleuritic chest pain) that is not clinically stable
  • Pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula.
  • Moderate to severe hepatic impairment
  • History of significant bleeding within 3 months before randomization.
  • History of solid organ transplantation
  • Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study
  • Unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption)
  • Known hypersensitivity or allergy to the active pharmaceutical ingredients or any component of the study intervention formulations
  • Received colony-stimulating factors [eg, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GMCSF) or recombinant erythropoietin (EPO)] within 28 days before randomization
  • Prior treatment with belzutifan or another hypoxia-inducible factor (HIF)-2α inhibitor
  • Prior treatment with lenvatinib
  • Prior treatment with cabozantinib
  • Currently participating in a study of an investigational agent or using an investigational device
  • Active infection requiring systemic therapy
  • History of human immunodeficiency virus (HIV) infection
  • History of hepatitis B or known active hepatitis C infection

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Belzutifan + Lenvatinib

Participants received daily oral dose of belzutifan 120 mg and lenvatinib 20 mg until progressive disease or discontinuation.

Oral administration

다른 이름들:
  • MK-6482
  • PT2977
  • 웰리렉™

Oral administration

다른 이름들:
  • E7080
  • 렌비마
  • MK-7902
활성 비교기: Cabozantinib

Participants received daily oral dose of cabozantinib 60 mg until progressive disease or discontinuation.

Oral administration

다른 이름들:
  • BMS-907351
  • 카보메틱스
  • 코메트릭
  • XL184

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
기간: Up to approximately 34 months

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review will be presented.

Up to approximately 34 months
Overall Survival (OS)
기간: Up to approximately 44 months

OS is defined as time from randomization to death due to any cause.

Up to approximately 44 months

2차 결과 측정

결과 측정
측정값 설명
기간
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
기간: Up to approximately 24 months

ORR is defined as the percentage of participants who have a complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 will be presented.

Up to approximately 24 months
Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
기간: Up to approximately 44 months

For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death. The DOR as assessed by blinded independent central review will be presented.

Up to approximately 44 months
Number of Participants Who Experienced One or More Adverse Events (AEs)
기간: Up to approximately 44 months

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Up to approximately 44 months
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
기간: Up to approximately 44 months

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Up to approximately 44 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 연구 책임자: Medical Director, Merck Sharp & Dohme LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 2월 25일

기본 완료 (실제)

2026년 2월 2일

연구 완료 (추정된)

2027년 2월 11일

연구 등록 날짜

최초 제출

2020년 10월 9일

QC 기준을 충족하는 최초 제출

2020년 10월 9일

처음 게시됨 (실제)

2020년 10월 14일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 4일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 6482-011
  • MK-6482-011 (기타 식별자: MSD)
  • jRCT2031210311 (기타 식별자: jRCT(Japan Registry of Clinical Trials))
  • 2020-002075-35 (EudraCT 번호)
  • U1111-1302-2815 (레지스트리 식별자: UTN)
  • 2024-510620-39-00 (레지스트리 식별자: EU CT)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .